MedPath

use of ivabradine - a heart rate lowering drug, to reduce heart rate and improve blood pressure in patients with liver disease and sepsis

Phase 2
Completed
Conditions
Health Condition 1: K746- Other and unspecified cirrhosis ofliver
Registration Number
CTRI/2020/07/026628
Lead Sponsor
Amal Francis Sam
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Not specified
Target Recruitment
66
Inclusion Criteria

patients with Child-Pugh A or B cirrhosis with septic shock (as per sepsis 3 guidelines) and Unexplained tachycardia with a heart rate more than 100/min for more 30 minutes

Exclusion Criteria

Acute liver failure

Patients with bradyarrhythmia and tachyarrythmia except sinus tachycardia

Patients on terlipressin therapy

CKD stage 5

Gastric residual volume or aspirate more than 500ml/6hrs

Pregnant patients

Patients who donâ??t give consent

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath